Cargando…
BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
Early T-cell precursor-acute lymphoblastic leukemia (ETP-ALL) has been identified as a high-risk subtype of pediatric T-cell acute lymphoblastic leukemia (T-ALL). Conventional chemotherapy is not fully effective for this subtype of leukemia; therefore, potential therapeutic targets need to be explor...
Autores principales: | Kawashima-Goto, Sachiko, Imamura, Toshihiko, Tomoyasu, Chihiro, Yano, Mio, Yoshida, Hideki, Fujiki, Atsushi, Tamura, Shinichi, Osone, Shinya, Ishida, Hiroyuki, Morimoto, Akira, Kuroda, Hiroshi, Hosoi, Hajime |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501565/ https://www.ncbi.nlm.nih.gov/pubmed/26172269 http://dx.doi.org/10.1371/journal.pone.0132926 |
Ejemplares similares
-
ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012) -
ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells
por: Yin, Pei, et al.
Publicado: (2016) -
ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011) -
Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016) -
BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy
por: Pedro, Jose Manuel Bravo-San, et al.
Publicado: (2015)